ArticleBrain : a journal of neurology2019
Reply: LATE to the PART-y.
Abstract readLetterComment
In one paragraph
Article in Brain : a journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change.Journal of neuropathology and experimental neurology · 2026Article
- Unraveling the clinical-pathological correlations of subjects with isolated and mixed neurodegenerative processes in the National Alzheimer's Coordinating Center dataset.Journal of neuropathology and experimental neurology · 2025Article
- New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS.Journal of neuropathology and experimental neurology · 2025Review
- Production and characterization of novel monoclonal antibodies against pathological human TDP-43 proteins.Journal of neuropathology and experimental neurology · 2024Article
- Limbic-predominant age-related TDP-43 encephalopathy (LATE-NC): Co-pathologies and genetic risk factors provide clues about pathogenesis.Journal of neuropathology and experimental neurology · 2024Review
- Cognitive symptoms progress with limbic-predominant age-related TDP-43 encephalopathy stage and co-occurrence with Alzheimer disease.Journal of neuropathology and experimental neurology · 2023Article
- Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases.Nature reviews. Neurology · 2023Review
- When Alzheimer's is LATE: Why Does it Matter?Annals of neurology · 2023Review
- Multiple gene variants linked to Alzheimer's-type clinical dementia via GWAS are also associated with non-Alzheimer's neuropathologic entities.Neurobiology of disease · 2022Article
- Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts.Acta neuropathologica · 2022Article
- Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis.Neurology · 2022Article
- Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP.Journal of neuropathology and experimental neurology · 2021Article
- Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration.Brain : a journal of neurology · 2020Article
Corrections and comments
- Comment on
Authors and funding
30 authors.
Peter T NelsonUniversity of Kentucky, Lexington, KY, USA.
Dennis W DicksonMayo Clinic, Jacksonville, FL, USA.
John Q TrojanowskiUniversity of Pennsylvania, Philadelphia, PA, USA.
Clifford R JackMayo Clinic, Rochester, MN, USA.
Patricia A BoyleRush University Medical Center, Chicago, IL, USA.
Konstantinos ArfanakisRush University Medical Center, Chicago, IL, USA.
Rosa RademakersMayo Clinic, Jacksonville, FL, USA.
Irina AlafuzoffUppsala University, Uppsala, Sweden.
Johannes AttemsNewcastle University, Newcastle upon Tyne, UK.
Carol BrayneUniversity of Cambridge, Cambridge, UK.
Ian T S Coyle-GilchristUniversity of Cambridge, Cambridge, UK.
David W FardoUniversity of Kentucky, Lexington, KY, USA.
Margaret E FlanaganUniversity of Minnesota, Minneapolis, MN, USA.
Glenda HallidayThe University of Sydney Brain and Mind Centre and Central Clinical School Faculty of Medicine and Health, Sydney, Australia.
Sally HunterUniversity of Cambridge, Cambridge, UK.
Gregory A JichaUniversity of Kentucky, Lexington, KY, USA.
Yuriko KatsumataUniversity of Kentucky, Lexington, KY, USA.
Claudia H KawasUniversity of California, Irvine, CA, USA.
C Dirk KeeneUniversity of Washington, Seattle, WA, USA.
Gabor G KovacsUniversity of Toronto, Toronta, Canada.
Walter A KukullUniversity of Washington, Seattle, WA, USA.
Allan I LeveyEmory University, Atlanta, GA, USA.
Nazanin MakkinejadIllinois Institute of Technology, Chicago, IL, USA.
Thomas J MontineStanford University, Stanford, CA, USA.
Melissa E MurrayMayo Clinic, Jacksonville, FL, USA.
Sukriti NagRush University Medical Center, Chicago, IL, USA.
William W SeeleyUniversity of California, San Francisco, CA, USA.
Reisa A SperlingHarvard University, Cambridge, MA, USA.
Charles L WhiteUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Julie A SchneiderRush University Medical Center, Chicago, IL, USA.
Funding
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MTransgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9MUPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DETRE, JOHN A · 1991 to 2020
$35.1MUniversity of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI GOLD, BRIAN TIMOTHY, VAN ELDIK, LINDA J · 2006 to 2020
$23.3MNeuropathological Characterization of 'CTE'R01NS094003 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Douglas Hamilton Smith, William Stewart · 2016 to 2026
$5.1MClinicopathologic and Neuroimaging Differences in Alzheimer's Disease VariantsR01AG054449 · NIA · MAYO CLINIC JACKSONVILLE · PI MURRAY, MELISSA ERIN · 2017 to 2021
$3.9MGenomic Architecture of a Key Alzheimer's Disease Mimic: CARTSR56AG057191 · NIA · UNIVERSITY OF KENTUCKY · PI FARDO, DAVID WILLIAM · 2019 to 2020
$1.1MNIA NIH HHS P01 AG017586NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG028383NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG054449NIA NIH HHS R56 AG057191NINDS NIH HHS R01 NS094003
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.